PIM1 and prostate carcinoma: In support of this notion, Siu and colleagues previously demonstrated in prostate cancer models that PIM-1 inhibition upregulates MIG6 [59], a negative regulator of EGFR signaling [60], thereby inhibiting EGFR/MAPK activation.